Litigation Details for Genentech, Inc v. JHL Biotech, Inc. (N.D. Cal. 2018)
✉ Email this page to a colleague
Genentech, Inc v. JHL Biotech, Inc. (N.D. Cal. 2018)
Docket | ⤷ Try a Trial | Date Filed | 2018-10-29 |
Court | District Court, N.D. California | Date Terminated | 2021-12-13 |
Cause | 18:1836(b) - Civil Action to Protect Trade Secrets | Assigned To | William Haskell Alsup |
Jury Demand | Both | Referred To | Sallie Kim |
Parties | XANTHE LAM | ||
Patents | 8,013,088; 9,226,961 | ||
Attorneys | Amy E Craig | ||
Firms | Keker Van Nest & Peters LLP | ||
Link to Docket | External link to docket |
Biologic Drugs cited in Genentech, Inc v. JHL Biotech, Inc.
Details for Genentech, Inc v. JHL Biotech, Inc. (N.D. Cal. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-10-29 | 1 | Complaint | feature to produce 12 a reference biologic.”8 13 88. To obtain the comparative analytical data… lose patent protection and many large monoclonal antibody therapies are coming 4 off patent globally…biosimilar versions of innovators’ medicines for which patent 14 protection has expired, and bring those biosimilar…growth is based in part on the fact that the primary patent 26 5 U.S. Dep’t of Health & Human | External link to document |
2019-06-17 | 218 | Amended Complaint | 12 a reference biologic.”8 13 88. To obtain the comparative analytical…biosimilar versions of innovators’ medicines for which patent 9 protection has expired, and bring…growth is based in part on the fact that the primary patent 26 5 U.S. Dep’t of…pharmaceutical products 3 are expected to lose patent protection and many large monoclonal antibody therapies… therapies are coming 4 off patent globally after 2018.” JHL’s website goes on to tout the | External link to document |
2019-01-03 | 77 | Opposition/Response to Motion | various publications, including Genentech US patent 9,226,961. (See 2 id. ¶154.) And …annually as of 2013 have recently lost patent protection or will lose patent protection 20 in the next few…Biosimilars are enabled by the expiration of numerous patents and by changes 18 to the pathway for regulatory…competing products as soon as the reference drugs’ patents expire, it is important for JHL 3 to seek regulatory…following the Supreme Court’s rejection of it in the patent context. eBay 20 Inc. v. MercExchange, L.L.C. | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |